• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Reversing the paradigm: protein kinase C as a tumor suppressor.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Newton, A
    Brognard, John
    Affiliation
    Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093-0721, USA
    Issue Date
    2017-03-07
    
    Metadata
    Show full item record
    Abstract
    The discovery in the 1980s that protein kinase C (PKC) is a receptor for the tumor-promoting phorbol esters fueled the dogma that PKC is an oncoprotein. Yet 30+ years of clinical trials for cancer using PKC inhibitors not only failed, but in some instances worsened patient outcome. The recent analysis of cancer-associated mutations, from diverse cancers and throughout the PKC family, revealed that PKC isozymes are generally inactivated in cancer, supporting a tumor suppressive function. In keeping with a bona fide tumor suppressive role, germline causal loss-of-function (LOF) mutations in one isozyme have recently been identified in lymphoproliferative disorders. Thus, strategies in cancer treatment should focus on restoring rather than inhibiting PKC.
    Citation
    Reversing the paradigm: protein kinase C as a tumor suppressor. 2017, Trends Pharmacol Sci
    Journal
    Trends in Pharmacological Sciences
    URI
    http://hdl.handle.net/10541/620252
    DOI
    10.1016/j.tips.2017.02.002
    PubMed ID
    28283201
    Type
    Article
    Language
    en
    ISSN
    1873-3735
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.tips.2017.02.002
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Protein kinase C as a tumor suppressor.
    • Authors: Newton AC
    • Issue date: 2018 Feb
    • Protein kinase C: perfectly balanced.
    • Authors: Newton AC
    • Issue date: 2018 Apr
    • Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor.
    • Authors: Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, Hunter T, Brognard J, Newton AC
    • Issue date: 2015 Jan 29
    • PHLPPing the balance: restoration of protein kinase C in cancer.
    • Authors: Tovell H, Newton AC
    • Issue date: 2021 Jan 29
    • Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression.
    • Authors: Isakov N
    • Issue date: 2018 Feb
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.